Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ThromboGenics |
---|---|
Information provided by: | ThromboGenics |
ClinicalTrials.gov Identifier: | NCT00123279 |
The purpose of this trial is to evaluate the safety and preliminary efficacy of different doses and several exposure times of intravitreal microplasmin in the setting of pars plana vitrectomy for vitreomacular traction maculopathy.
Condition | Intervention | Phase |
---|---|---|
Vitreomacular Traction Maculopathy Eye Diseases |
Drug: Microplasmin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Dose-Escalation Clinical Trial of Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy for Vitreomacular Traction Maculopathy |
Enrollment: | 60 |
Study Start Date: | December 2004 |
Study Completion Date: | November 2008 |
Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
2: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
3: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
4: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
5: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
6: Experimental |
Drug: Microplasmin
25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
|
Study drug will be administered in the mid-vitreous by injection. Patients will be enrolled into the cohorts in a sequential dose/time-escalating fashion. To ensure that enrolment is evenly balanced across eligible conditions, enrolment of any specific underlying disease type into any cohort will be capped at five (5) patients.
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with vitreomacular traction maculopathy for whom vitrectomy is indicated, according to the principal investigator, including:
Exclusion Criteria:
Belgium | |
University Hospital Gasthuisberg | |
Leuven, Belgium, B-3000 | |
Germany | |
Ludwig-Maximilians-University | |
Munich, Germany, D-80336 | |
Netherlands | |
Oogziekenhuis Rotterdam | |
Rotterdam, Netherlands, 3011 BH | |
Academic Medical Center, University of Amsterdam | |
Amsterdam, Netherlands, 1105 AZ |
Principal Investigator: | Marc deSmet, Prof. Dr | Amsterdam Medical Center |
Responsible Party: | ThromboGenics ( Edith Van Dijkman ) |
Study ID Numbers: | TG-MV-001 |
Study First Received: | July 21, 2005 |
Last Updated: | November 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00123279 |
Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines; Belgium: Institutional Review Board; Germany: Federal Institute for Drugs and Medical Devices |
diabetic macular edema macular hole vitreomacular traction syndrome |
Macular Edema Eye Diseases Edema |